pharma · Schizophrenia · Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis · MPLT
MapLight Therapeutics
MapLight Therapeutics is a pharma organization headquartered in atlanta, USA. It trades on NYSE under ticker MPLT. Primary therapeutic focus areas include Schizophrenia, Hallucinations and Delusions Associated with Alzhe
atlanta, USA HQ
2017 Founded
7 Employees
Public company Type
MPLT · NYSE Ticker
Company details
- Status
- Public
- HQ
- atlanta, USA
- Founded
- 2017
- Employees
- 7
- Programs
- 5
- Drugs
- 5
- Patents
- 0
ML-007C-MA
Phase 2 · small molecule · Psychosis Associated With Alzheimer's Disease
ML-007C-MA for Psychosis Associated With Alzheimer's Disease is a Phase 2 program (small_molecule) at MapLight Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code ML-007C-MA-221
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MapLight Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Psychosis Associated With Alzheimer's Disease
- Status
- active
- Trials
- 2